Project Grant R01CA288530

Award Date 6/10/24
Completion Date 5/31/29
Dollars Obligated $724K
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) aims to develop and evaluate an intervention to improve cervical cancer screening and follow-up rates in three diverse, underserved populations: urban inner city Blacks/Haitians (Boston), Hispanic immigrants (Florida), and Hawaiian Natives/Pacific Islanders (Hawaii). The $753,446 award will be used to adapt a successful HPV vaccination intervention for cervical cancer screening,...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $710,656 to Loma Linda University to develop and validate the PROSPECT (Premalignant Oral Lesions Pathology and Epigenetic Risk Prediction Tool), a multi-stage, multi-modal biomarker to risk-stratify oral premalignant lesions (OPL) and predict progression to oral cavity squamous cell carcinoma. The project aims to: 1) Train deep learning models to predict OPL progression...
The National Cancer Institute (NCI) awarded a $171,989 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of Florida. The goal of this 5-year grant, with a start date of September 1, 2024, is to adapt an evidence-based intervention called "PINPOINT" to improve cervical cancer screening and care outcomes among women with chronic conditions like obesity and type 2 diabetes, as well as social vulnerabilities such as poverty and rural residence. The...
The National Cancer Institute (NCI) awarded Emory University a $708,091 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to test the effectiveness of the Algorithm-Enabled Patients Activated in Cancer Care through Teams (A-PACT) intervention. A-PACT uses machine learning algorithms to automatically identify high-risk cancer patients who would benefit from structured education and engagement in goals of care conversations between oncology visits. The project aims...
This $547,047 Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), aims to test the bundling of multicancer prevention services, including breast and colorectal cancer screening and genetic testing, for non-Hispanic Black and Hispanic women aged 45-74. The study will be conducted by Georgetown University and will evaluate the effectiveness and feasibility of integrating community-based breast cancer screening...
This federal Project Grant award of $368,070.00 from the National Cancer Institute (NCI), under the CFDA 93.393 Cancer Cause and Prevention Research program, supports research to identify and address barriers in the cervical cancer treatment cascade among women with HIV in South Africa. The primary awardee, Trustees of Boston University, will conduct qualitative interviews and a pilot randomized controlled trial to develop a multi-level retention care intervention tailored to the unique needs of...
This Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund a hybrid type III effectiveness-implementation trial to test best practices for deploying a "screen and treat" approach to cervical cancer screening utilizing self-collected HPV DNA testing within HIV care and treatment facilities in Mozambique. The 5-year, $643,363 project aims to improve access to affordable HPV testing and promote...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $706,771 to the H. Lee Moffitt Cancer Center and Research Institute to conduct a hybrid effectiveness-implementation study. The goal is to evaluate the impact of a precision prevention intervention to improve skin cancer prevention behaviors among diverse patients in low-resourced, community primary care settings. The study will recruit 1,430 participants from Federally...
This K08 Career Development Award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $197,640 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop implementation strategies for initiating colorectal cancer (CRC) screening in previously unscreened individuals aged 45 to 54 at a predominantly Black community health center in Boston, Massachusetts. The project aims to: (1) identify system-level determinants of CRC...
The National Cancer Institute (NCI) awarded a $622,913 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of California, Los Angeles (UCLA) to evaluate a multilevel intervention to increase colonoscopic follow-up after abnormal stool-based colorectal cancer screening in a community safety-net setting. The project aims to: 1) Compare the effectiveness of the multilevel intervention to usual care on receipt of colonoscopy within 6 months of an...

PERSONALIZED RISK-BASED FOLLOW-UP OF CERVICAL CANCER SCREENING IN PRACTICE (PREDICT) - ABSTRACT CERVICAL CANCER IS HIGHLY PREVENTABLE WHEN DETECTED EARLY AND MANAGED APPROPRIATELY; TODAY IT IS MOST OFTEN DIAGNOSED IN UNDER-SCREENED INDIVIDUALS OR AFTER A FAILURE TO FOLLOW-UP ABNORMAL SCREENING RESULTS. CERVICAL CANCER SCREENING AND MANAGEMENT (CCSM) IS COMPLEX AS BOTH SCREENING MODALITIES AND MANAGEMENT GUIDELINES HAVE RECENTLY EVOLVED. THE 2018 US PREVENTIVE SERVICES TASK FORCE SCREENING GUIDELINES RECOMMEND 3 STRATEGIES TO SCREEN FOR CERVICAL CANCER: PAP TEST WITH OPTION OF REFLEX HUMAN PAPILLOMA VIRUS (HPV) TESTING, PAP/ HPV CO-TESTING, AND HPV ALONE. THE 2019 AMERICAN SOCIETY FOR COLPOSCOPY AND CERVICAL PATHOLOGY (ASCCP) GUIDELINES FOR MANAGING ABNORMAL RESULTS REFLECT THE PRINCIPLE OF "EQUAL MANAGEMENT FOR EQUAL RISKS," PROMOTING HIGHLY PERSONALIZED MANAGEMENT, WITH SYNTHESIS OF CURRENT AND PRIOR RESULTS, TO MAXIMIZE BENEFITS OF CANCER PREVENTION WHILE MINIMIZING HARMS OF OVER-TESTING AND OVER-TREATMENT. YET, THE COMPLEXITY OF THESE CURRENT EVIDENCE-BASED CLINICAL GUIDELINES MAKES IT CHALLENGING FOR CLINICIANS TO IMPLEMENT IN PRACTICE. LACK OF INTEGRATION OF THE ASCCP ALGORITHMS WITH ELECTRONIC HEALTH RECORDS (EHRS) IS AN IMPORTANT BARRIER TO MANAGEMENT. AS A RESULT, INCOMPLETE AND INCORRECT FOLLOW-UP REPRESENTS AN ONGOING AND GROWING CHALLENGE, INVOLVING COMPLEX INTERACTIONS AMONG PATIENTS, PRIMARY CARE PRACTITIONERS AND SPECIALISTS. IMPLEMENTING PERSONALIZED RISK-BASED CERVICAL CANCER SCREENING REQUIRES ADDRESSING BARRIERS AT INDIVIDUAL, BOTH PATIENT AND PRACTITIONER, LEVELS AS WELL AS AT CARE TEAM AND HEALTH SYSTEM LEVELS. WE PROPOSE TO DEVELOP, TEST AND DISSEMINATE A HEALTH INFORMATION TECHNOLOGY-ENABLED, MULTILEVEL, STEPPED CARE INTERVENTION GROUNDED IN PRIMARY CARE, PREDICT (PERSONALIZED RISK-BASED FOLLOW-UP OF CERVICAL CANCER SCREENING IN PRACTICE) FOR THE CERVICAL CANCER SCREENING CONTINUUM. PREDICT IS DESIGNED TO BE HIGHLY SCALABLE, USING AN OPEN SOURCE CCSM TOOL, INTEGRATED USING NATIONAL DATA STANDARDS ENDORSED BY THE 21ST CENTURY CURES ACT FINAL RULE. KEY PREDICT COMPONENTS INCLUDE: SYSTEM REDESIGN TO PROMOTE IDENTIFICATION, TRACKING, AND EHR-INTEGRATION OF CLINICAL GUIDELINES TO PROMOTE BOTH VISIT-BASED AND POPULATION MANAGEMENT; USE OF INDIVIDUAL PATIENT AND PRACTITIONER REMINDERS AND TOOLS TO PROMOTE ENGAGEMENT; AND ENHANCE TEAM COORDINATION THROUGH AN EFFICIENT "STEPPED CARE" APPROACH. THE EFFECTIVENESS AND IMPLEMENTATION OF PREDICT WILL BE EVALUATED BY CONDUCTING A 3-ARM CLUSTER RANDOMIZED CONTROLLED TRIAL (STANDARD CARE VS. VISIT-BASED MANAGEMENT VS. POPULATION OUTREACH) OF INDIVIDUALS IN 4 PRIMARY CARE NETWORKS. THE DESIGN WILL ALLOW US TO EXAMINE THE MARGINAL AND CUMULATIVE EFFECTIVENESS OF THE INTERVENTION COMPONENTS ON THE PRIMARY EFFECTIVENESS OUTCOME OF RECEIPT OF APPROPRIATE CCSM WITHIN 120-DAYS OF BECOMING DUE FOR CARE. GUIDED BY IMPLEMENTATION EVALUATION (RE-AIM QUEST) AND DETERMINATION (CFIR) FRAMEWORKS, WE WILL ASSESS THE REACH, ACCEPTABILITY, ADOPTION, IMPLEMENTATION AND MAINTENANCE/ SUSTAINABILITY OF THE INTERVENTION.

Posted 5/31/24, 12:00 AM